Accelerate Development of New Therapies for Childhood Cryptosporidium Infection (Round 18) pg2
Funds for NGOs Last date 9 Nov 2016
What we are looking for:
This call is soliciting new tools and technologies that have potential i) to overcome the technical barriers in working with Cryptosporidium that have historically hampered progress, and ii) to improve our ability to develop and translate active compounds into effective therapies for treatment of pediatric cryptosporidiosis. The goal of this call is to develop broadly applicable approaches that can be used to accelerate development of therapeutic interventions, rather than to support the development of specific interventions themselves.
A few of the many potential examples to be considered include:
Development of novel moderate- to high-throughput screening approaches that target different life-stages of the parasite or that recapitulate aspects of the realistic in vivo environment of the parasite (e.g. gut-on-a-chip or other like technologies);
New methods for the identification and validation of drug targets in Cryptosporidium,as well as methods for interrogating validated targets within the context of whole cell phenotypic assays (e.g. target-based reporter assays);
Novel methods for genetic manipulation of the Cryptosporidium genome, particularly those that allow regulated gene expression;
Systematic approaches to explore opportunities for host-directed therapies, based on a rational understanding of parasite metabolism and parasite/host interactions;
Validation of small animal disease models that are more tractable than the calf or gnotobiotic piglet, but which model human infection and disease (particularly valuable if immunocompetent and/or supportive of C. hominis infection);
Assessment of biomarkers with potential to monitor clinical drug efficacy, specifically with regard to parasite elimination;
Pre-clinical in vitro, in vivo, or in silico models to assess the role of co-infection, the microbiome, and gut dysfunction on drug efficacy;
Novel methods to establish PK/PD relationships for anti-cryptosporidial drugs in the context of gut location of pathogen infection and disease pathology.
We will not consider funding for:
Applications focused on fundamental scientific research into parasite biology;
Epidemiological studies to further define the burden of Cryptosporidium infection;
Development of Cryptosporidium vaccines or other preventative approaches, including improved sanitation or environmental interventions;
Development of point-of-care diagnostics for Cryptosporidium;
Development of specific therapeutic interventions, including small molecules, pre-biotics, probiotics, “functional foods”, or other microbiome-directed interventions;
Proposals involving clinical trials in human volunteers or patients;
Ideas or approaches that are not novel and innovative, but rather application of well-established methods or approaches.
Some information contained in this website has been collected from various sources including other websites
on the internet. While all the information is deemed to be correct, NGOPortal.org has not verified them and does not endorse the accuracy of the information
published on this website. Readers are strongly advised to verify them on their own and use the information at their own risk.